Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,612.82
(
-0.18%
)
US TECH 100
23,734.40
(
-0.26%
)
Dow Jones
46,114.09
(
-0.24%
)
Brent Oil
103.40
(
-2.98%
)
Bitcoin
70,446.84
(
-1.12%
)
News Focus
News Focus

Replies to post #135655 on Biotech Values

Replies to #135655 on Biotech Values
icon url

masterlongevity

01/25/12 10:00 AM

#135658 RE: masterlongevity #135655

sorry 4% for >1
icon url

DewDiligence

01/25/12 8:15 PM

#135696 RE: masterlongevity #135655

Your 4% figure for >=2 DM agents in the next five years is a little too high, IMO. I would say it’s in the 1-2% range.
icon url

DewDiligence

01/31/12 11:27 PM

#136190 RE: masterlongevity #135655

The phase-3 Bapineuzumab trials being conducted by PFE do not have futility analyses. Results are due in mid 2012. (Source: PFE’s 4Q11 CC)
icon url

DewDiligence

02/21/12 7:08 PM

#137528 RE: masterlongevity #135655

Shorting the amyloid hypothesis in AD:

http://www.thestreet.com/print/story/11425418.html